4 ms·
Amazing and very cool! A couple of questions, if you can share at this time, since this resonates with my interests. - Which patient/donor cell type are these
by car 5y ago
Amazing and very cool! A couple of questions, if you can share at this time, since this resonates with my interests.
- Which patient/donor cell type are these immune organoids derived from?
- Are the organoids made with induced pluripotent stem cell technology?
- What is part of the workup post treatment, e.g. histology, NGS? If NGS, what kind (WGS, WES, RNASeq) and technologies (Illumina, PacBio, ONT)?
- Are you looking for mutations from the drug and vaccine treatment (e.g. comet assay, Duplex-Seq)?
- rdifazio 5y agoThanks for the feedback! I'm happy to share more. - They're derived from secondary lymphoid tissue. We're trying to biobank as broadly as we can to capture sex, age, race, HLA, genetics, and other characteristics in a wide net. - These are not iPSC-derived organoids. - This depends on the readout but workup post treatment so far has included histology, immunofluorescence, serology (ELISA, SPR, etc.), CyTOF and other flow, broad RNA-seq, bulk and single cell repertoire sequencing for B and T cells, and MSD/Luminex. - We haven't looked for mutations from drug and vaccine treatment. We'd love to know more about what you're thinking there.